Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults

Launched by GLAXOSMITHKLINE · Feb 9, 2006

Keywords

ClinConnect Summary

This is a long-term follow-up study at Years 11, 12, 13, 14 and 15 after primary vaccination with GSK Biologicals' hepatitis A/hepatitis B vaccine (three-dose schedule with 3 different lots). To evaluate the long-term antibody persistence, volunteers will be bled at Years 11, 12, 13, 14 and 15 after the first vaccine dose of the primary vaccination course to determine their anti-HAV and anti-HBs antibody concentrations.

No additional subjects will be recruited in the course of this extension study. If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects who had consented to participate in the long-term follow-up studies at the previous long-term blood sampling time points
• • Written informed consent will have been obtained from each subject. before the blood sampling visit of each year.